Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,1724€
Last updated
05/06/2026 - 21:25
-1,49%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and Presentations
Financial Results
Governance
Voting Rights Information – May 2026
No results found.
2026 Annual General Meeting – Voting Form
No results found.
AGM 2026 – Resolutions
No results found.
AGM 2026 – Candidate Profiles
No results found.
AGM 2026 – Notice of Meeting for Registered Shareholders
No results found.
News
Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026
Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis
Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
ALLINVEST SECURITIES
Thibaut Voglimacci – Stephanopoli
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France